The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Pleural effusion (uni- or bilateral) (can accompany DI-LDs)
Publications
The burden of managing pleural effusions in patients with chronic myelogenous leukemia post-imatinib failure: A literature-based economic analysis.
International journal of general medicine 2010 Apr 08;3;31-6 — 2010 Apr 08 — 31-6
Prominent pleural effusion possibly due to imatinib mesylate in adult Philadelphia chromosome-positive acute lymphoblastic leukemia.
Internal medicine (Tokyo, Japan) 2006;45;339-40 — 2006 — 339-40
Pleural-pericardic effusion as uncommon complication in CML patients treated with Imatinib.
European journal of haematology 2005 Jan;74;89-90 — 2005 Jan — 89-90
Unexpected pleural effusions in 3 pediatric patients treated with STI-571.
Journal of pediatric hematology/oncology 2002 Nov;24;694-5 — 2002 Nov — 694-5